Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
Clinical Epigenetics|January 3, 2024
MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancerHanghang Zhang, Chen Huang, John Gordon, et al.
Plos Genetics|August 30, 2008
An Sp1/Sp3 binding polymorphism confers methylation protectionYanis A Boumber, Yutaka Kondo, Xuqi Chen, et al.
The Oncologist|August 19, 2025
HER2 Alterations across Solid Tumors: Implications for Comprehensive TestingAhmed Ismail, Chimay Jani, Nusrat Jahan, et al.
Cancer Research|March 3, 2007
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosisYanis A Boumber, Yutaka Kondo, Xuqi Chen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 8, 2007
Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors)In-Seon Choi, Marcos R H Estecio, Yasuhiko Nagano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patientsThushangi N Pathiraja, Priya B Shetty, Jaroslav Jelinek, et al.
Epigenetics|December 27, 2022
Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosaAng Sun, Pyounghwa Park, Lauren Cole, et al.
Blood|February 15, 2003
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemiaLanLan Shen, Minoru Toyota, Yutaka Kondo, et al.
Cancer Research|August 28, 2003
Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancerMarsha L Frazier, Lixuan Xi, Jihong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinomaJared A Gollob, Catherine J Sciambi, Bercedis L Peterson, et al.
Pageof 25